.png){kind=logo}
About Us
We opened in February 2021 as a private psychiatric-psychotherapeutic practice with a focus on ketamine-augmented and integration-focused psychotherapy.
Now, with our expansion in March 2024, we’re proud to have grown into a fully equipped day clinic, extending our therapeutic range while staying true to our core: innovative, compassionate, and science-based mental healthcare.
Dr. Andrea Jungaberle
Chief physician
Pioneering the research of psychedelics for the treatment of depression - the EPIsoDE psilocybin study
Our chief physician, Prof. Dr. Gerhard Gründer, began the first study in Germany to treat depression with the psychedelic substance psilocybin in 2021 - with the last patient out in February 2024.
This high-quality Phase II study with 144 participants was conducted at the Central Institute of Mental Health in Mannheim and at the Charité University Medicine Berlin with our partner company MIND Foundation being a partner in the consortium. Our chief physician, Dr. Andrea Jungaberle, also gained clinical and therapeutic experience with psilocybin in this study. Our approach to ketamine draws on these many years of experience with psychedelic psychotherapy. This distinguishes our approach significantly from the pure ketamine infusion treatments used in many other institutions.
Book tip:
"Stop taking psychotropic drugs? Why, when, and how?"
Prof. Dr. med. Gerhard Gründer
